IMCgp100 is an ImmTAC reagent targeting the melanoma-associated antigen gp100. It is currently undergoing Phase I/II clinical testing as a monotherapy for the treatment of patients with advanced cutaneous and uveal melanoma
Combination studies will also test IMCgp100 with other immunotherapies, including a Phase I/II study with checkpoint inhibitors durvalumab and tremelimumab from MedImmune (AstraZeneca), for patients with metastatic cutaneous melanoma.
IMCgp100 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of uveal melanoma and is a participant in the European Medicines Agency's (EMA) Adaptive Pathways Pilot Programme.
For more information on clinical trials involving IMCgp100 see clinicaltrials.gov.
Immunocore has established a comprehensive and regulatory approved preclinical assessment package for ImmTAC molecules to minimize the potential risks of treatment-related toxicities. The process comprises both molecular and cellular analyses and has been shown to be predictive of clinical observations.